{Reference Type}: English Abstract
{Title}: [Impact of NGS results on patient outcome with a multiform glioblastoma].
{Author}: Rom M;Schott R;Pencreac'h E;Cébula H;Cox D;Bender L;Antoni D;Lhermitte B;Noel G;
{Journal}: Cancer Radiother
{Volume}: 0
{Issue}: 0
{Year}: Jun 2022 14
{Factor}: 1.217
{DOI}: 10.1016/j.canrad.2022.01.002
{Abstract}: <B>OBJECTIVE: </B>Although some genetic alterations in glioblastoma (GBM) have been characterized, the prognostic value of these gene mutations is not yet established in patients treated with standard therapy.<BR><B>METHODS: </B>40 patients with newly diagnosed GBM, treated between July 2017 and December 2019, and who had genomic analysis were analyzed. Next-generation sequencing techniques (NGS) were used with a panel of 26 genes. Patients were grouped according to MGMT status, the presence or absence of at least one mutated gene on the panel, and p53 expression by immunohistochemistry.<BR><B>RESULTS: </B>the median follow-up was 11.5 months (1.0-37). For all patients, the median duration of progression-free survival was 8 months (95% CI, 5.3-10.7) and the median overall survival (OS) was 17 months (95% CI, 7.5-26.5). Progression-free and overall survival were significantly different according to MGMT status but not according to NGS and p53 status. Three groups of patients according to different combined status could be distinguished due to significant differences in overall survival.<BR><B>CONCLUSIONS: </B>we have shown that the presence of MGMT promoter methylation is a good prognostic factor. By grouping the patients according to their MGMT, NGS and p53 status, three groups of patients could be separated according to their overall survival. However, these results must be confirmed on a larger number of patients.